Janssen 75276617AML3001 (cAMeLot-2)
Learning More About This Study:
The purpose of this study is to evaluate the safety and effectiveness of a combination of bleximenib, venetoclax, and azacitidine in individuals with newly diagnosed acute myeloid leukemia who have specific genetic changes (KMT2A rearrangements or NPM1 mutations) and are not eligible for intensive chemotherapy. These genetic alterations can influence how AML develops and responds to treatment. Researchers aim to better understand how this combination therapy impacts disease response, treatment tolerance, and overall outcomes in this patient population.
The purpose of this study is to evaluate the safety and effectiveness of a combination of bleximenib, venetoclax, and azacitidine in individuals with newly diagnosed acute myeloid leukemia who have specific genetic changes (KMT2A rearrangements or NPM1 mutations) and are not eligible for intensive chemotherapy. These genetic alterations can influence how AML develops and responds to treatment. Researchers aim to better understand how this combination therapy impacts disease response, treatment tolerance, and overall outcomes in this patient population.
Disclaimer:
This summary is for informational purposes only. It does not invite participation, provide medical advice, or suggest that any investigational medication is safe, effective, or approved. Individuals diagnosed with acute myeloid leukemia should consult their healthcare provider for personalized medical guidance.
This summary is for informational purposes only. It does not invite participation, provide medical advice, or suggest that any investigational medication is safe, effective, or approved. Individuals diagnosed with acute myeloid leukemia should consult their healthcare provider for personalized medical guidance.